Citations (18)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Matthew Feldman & Jason Margolesky. (2023) Opicapone for the treatment of Parkinson’s disease: a review. International Journal of Neuroscience 133:5, pages 532-543.
Read now
Read now
Linda Azevedo Kauppila, Daniela Pimenta Silva & Joaquim J Ferreira. (2021) Clinical Utility of Opicapone in the Management of Parkinson’s Disease: A Short Review on Emerging Data and Place in Therapy. Degenerative Neurological and Neuromuscular Disease 11, pages 29-40.
Read now
Read now
András Salamon, Dénes Zádori, László Szpisjak, Péter Klivényi & László Vécsei. (2020) Fixed-dose combination therapy for Parkinson’s disease with a spotlight on entacapone in the past 20 years: a reduced pill burden and a simplified dosing regime. Expert Opinion on Pharmacotherapy 21:18, pages 2265-2278.
Read now
Read now
Articles from other publishers (15)
Zhengkang Su, Kaiyu Guan, Yunbin Liu, Hai Zhang, Zhengwei Huang, Miaomiao Zheng, Ya Zhu, He Zhang, Weihong Song & Xi Li. (2023) Developmental and behavioral toxicity assessment of opicapone in zebrafish embryos. Ecotoxicology and Environmental Safety 249, pages 114340.
Crossref
Crossref
Ana I. Loureiro, Francisco Rocha, Ana T. Santos, Nand Singh, Maria João Bonifácio, Rui Pinto, Laszlo E. Kiss & Patrício Soares‐da‐Silva. (2022) Absorption, metabolism and excretion of opicapone in human healthy volunteers. British Journal of Clinical Pharmacology 88:10, pages 4540-4551.
Crossref
Crossref
Pedro Cruz-Vicente, Ana M. Gonçalves, Jorge Barroca-Ferreira, Samuel M. Silvestre, Maria J. Romão, João A. Queiroz, Eugénia Gallardo & Luis A. Passarinha. (2022) Unveiling the biopathway for the design of novel COMT inhibitors. Drug Discovery Today 27:10, pages 103328.
Crossref
Crossref
Magdalena Żegleń, Katarzyna Śladowska, Paweł Kawalec & Tomasz Brzostek. (2022) Opicapone as an add-on to levodopa for reducing end-of-dose motor fluctuations in Parkinson’s disease: a systematic review and meta-analysis. Journal of Comparative Effectiveness Research 11:12, pages 889-904.
Crossref
Crossref
Amnon A. Berger, Ariel Winnick, Jonathan Izygon, Binil M. Jacob, Jessica S. Kaye, Rachel J. Kaye, Elisa E. Neuchat, Adam M. Kaye, Edward S. Alpaugh, Elyse M. Cornett, Andrew H. Han & Alan D. Kaye. (2022) Opicapone, a Novel Catechol-O-methyl Transferase Inhibitor, for Treatment of Parkinson’s Disease “Off” Episodes. Health Psychology Research 10:5.
Crossref
Crossref
Nayoung Kwak, Jinyoung Park, Hye-Young Kang, Myung-Jun Lee, Jae Kyung Suh & Hankil Lee. (2022) Efficacy and Safety of Opicapone for Motor Fluctuations as an Adjuvant to Levodopa Therapy in Patients with Parkinson’s Disease: A Systematic Review and Meta-Analysis. Journal of Parkinson's Disease 12:3, pages 773-783.
Crossref
Crossref
Amnon A. Berger, Christopher Robinson, Ariel Winnick, Jonathan Izygon, Binil M. Jacob, Mackenzie J. Noonan, Alan D. Kaye, Jessica S. Kaye, Adam M. Kaye, Elyse M. Cornett, Rutvij J. Shah, Omar Viswanath & Ivan Urits. (2021) Opicapone for the Treatment of Parkinson’s Disease "Off" Episodes: Pharmacology and Clinical Considerations. Clinical Drug Investigation 42:2, pages 127-135.
Crossref
Crossref
Ana I. Loureiro, Carlos Fernandes‐Lopes, Maria João Bonifácio, Filipa Sousa, László E. Kiss & Patricio Soares‐da‐Silva. (2021) Metabolism and disposition of opicapone in the rat and metabolic enzymes phenotyping. Pharmacology Research & Perspectives 10:1.
Crossref
Crossref
Na Liu, Liping Bai, Zhipeng Lu, Rou Gu, Dongdong Zhao, Fang Yan & Jie Bai. (2022) TRPV4 contributes to ER stress and inflammation: implications for Parkinson’s disease. Journal of Neuroinflammation 19:1.
Crossref
Crossref
Andries D. de Beer, Lesetja J. Legoabe, Anél Petzer & Jacobus P. Petzer. (2021) The inhibition of catechol O-methyltransferase and monoamine oxidase by tetralone and indanone derivatives substituted with the nitrocatechol moiety. Bioorganic Chemistry 114, pages 105130.
Crossref
Crossref
Yupin Su, Michael DePasquale, Gangling Liao, Ingrid Buchler, Gongliang Zhang, Spencer Byers, Gregory V. Carr, James Barrow & Huijun Wei. (2021) Membrane bound catechol-O-methytransferase is the dominant isoform for dopamine metabolism in PC12 cells and rat brain. European Journal of Pharmacology 896, pages 173909.
Crossref
Crossref
Juan Segura-Aguilar. 2021. Clinical Studies and Therapies in Parkinson's Disease. Clinical Studies and Therapies in Parkinson's Disease
209
212
.
Fernanda Rodríguez-Enríquez, María Carmen Costas-Lago, Pedro Besada, Miguel Alonso-Pena, Iria Torres-Terán, Dolores Viña, José Ángel Fontenla, Mattia Sturlese, Stefano Moro, Elias Quezada & Carmen Terán. (2020) Novel coumarin-pyridazine hybrids as selective MAO-B inhibitors for the Parkinson’s disease therapy. Bioorganic Chemistry 104, pages 104203.
Crossref
Crossref
Mary-Frances E. Hall & Frank C. Church. (2020) Integrative Medicine and Health Therapy for Parkinson Disease. Topics in Geriatric Rehabilitation 36:3, pages 176-186.
Crossref
Crossref
Rialette Hitge, Sharissa Smit, Anél Petzer & Jacobus P. Petzer. (2020) Evaluation of nitrocatechol chalcone and pyrazoline derivatives as inhibitors of catechol-O-methyltransferase and monoamine oxidase. Bioorganic & Medicinal Chemistry Letters 30:12, pages 127188.
Crossref
Crossref